The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer’s disease. Lecanemab, a humanized IgG1 monoclonal antibody that ...

With the number of Alzheimer’s cases increasing, the medical community needs treatments for this disease now more than ever. One experimental drug, lecanemab, has been hailed by some experts as the ...

The FDA's decision comes after clinical trial results indicated that lecanemab slows cognitive decline somewhat in people with mild impairment from Alzheimer's. But Biogen and Eisai's monoclonal ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

A new report details the case of a patient on the new experimental Alzheimer's drug, lecanemab, who died after experiencing numerous acute intracerebral hemorrhages during treatment with tissue ...

The FDA granted accelerated approval to Alzeihmer’s drug lecanemab (brand name Leqembi) on Friday, however, severe side effects and a death during a clinical trial possibly linked to the drug has many ...

Continuous treatment with lecanemab (Leqembi, Eisai/Biogen) demonstrated sustained disease-modifying benefit over 4 years in patients with early-stage Alzheimer’s disease (AD) enrolled in the ...

Lecanemab can only be used in the early stages of Alzheimer's. If you or a loved one are experiencing early signs of Alzheimer's diseases, such as consistent short-term memory loss or confusion about ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early Alzheimer's disease, initial findings from the CLARITY AD ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. According to the Institute for Clinical and Economic Review (ICER) ...